Join NIAID and make a difference! |
Health Scientist Administrator (Program Officer) - (COVID-19)Division of Allergy, Immunology, and Transplantation
NIAID is seeking exceptional and motivated candidates to serve as a program officer (regulatory affairs officer) within the Office of Regulatory Affairs in the Division of Allergy, Immunology, and Transplantation (DAIT).
Regulatory affairs officers maintain regulatory and quality assurance surveillance over all clinical trials and protocols supported by DAIT to ensure that trials are conducted in accordance with Food and Drug Administration (FDA) regulations; establish and monitor quality assurance standards and standard operating procedures regarding regulatory matters; review safety reports for DAIT-sponsored trials; act as liaisons for regulatory issues with the FDA, international regulatory authorities, and pharmaceutical companies; and coordinate and communicate with other domestic and international government agencies and with other DAIT components to ensure accurate and timely exchange of information on regulatory issues.
Qualifications
Candidates must be U.S. citizens and demonstrate that they have worked independently in planning, organizing, and conducting biomedical behavioral health or health-related research and served effectively in research program administration in these fields.
Experience in pharmaceutical drug development and the preparation of submissions to U.S. and/or international health authorities is preferred.
To Apply
View the Health Scientist Administrator (Program Officer & Scientific Review Officer) - (COVID-19) announcement NIH-GR-DH-20-10828064 now to prepare your application information. Apply to the vacancy announcement June 8 through June 12, 2020.
Visit NIAID Careers for more information about working in NIAID’s dynamic atmosphere!
HHS, NIH, and NIAID are equal opportunity employers.
|
sábado, 6 de junio de 2020
New NIAID Career Opportunity Opening 6/8 - Health Scientist Administrator (Program Officer) - (COVID-19)
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario